Value-Based Contracting Bill Aims For Bipartisan Political Support
Executive SummaryLegislation from Sens. Bill Cassidy and Mark Warner would eliminate barriers to value-based contracting for drugs reimbursed by public payers.
You may also be interested in...
Roche's Richard Peck says adoption of outcomes-based pricing in the US could be powerful incentive to study precision dosing, although he also calls on drugmakers to put out scientific examples.
Finance Committee chairman wants a provision allowing Medicaid to make installment payments for high-cost curative treatments in drug pricing legislation. But Democrats worry such a model might encourage high prices.
In JAMA editorial, former FDA chief supports drug importation under narrow circumstances as a way to reduce drug prices, marking a shift from his previous stance on the issue and that of other past agency heads. Essay, co-authored by former CMS Acting Administrator Andy Slavitt, calls importation "a workaround born of desperation."